Skip to main content
05_Bernardo_Franklin
© Photo: Bruna Guerra Photography

News categories: Honors & Funding

ERC Proof of Concept Grants for UNBIAS

European Research Council is supporting the journey from basic research to application

Prof. Bernardo Franklin from the Institute of Innate Immunity at the University Hospital Bonn has been awarded a Proof of Concept Grant by the European Research Council (ERC) as part of a program designed to help researchers translate their ideas from previous ERC projects into commercial applications. The project is awarded with a funding of €150,000, provided over a period of around one year.

ImmunoSensation2 member Prof. Dr. Bernardo S. Franklin studies hematopoietic stem cells (HSCs), which develop into different blood cells through processes of cell division and differentiation. “Bouts of inflammation that a person experiences as they get older will damage these stem cells,“ Bernardo S. Franklin says. “Processes like this cause hyperactivation of the innate immune system in the elderly.” This phenomenon, known as “inflammaging,” increases the risk of conditions including cardiovascular disease, diabetes and cancer, he adds.

“Wiping” the immune system’s harmful memories of inflammation


The project that has now secured ERC funding, which is entitled “Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation” (UNBIAS), aims to return HSCs to their original state in order to “wipe” the immune system’s harmful memories of inflammation. The researchers are using customized “mini-antibodies” known as nanobodies to achieve this. These antibodies, which are very small in relative terms, are taken from the blood of alpacas and can break up the places where inflammation develops.

Back in 2017, Franklin received a much-sought-after Starting Grant from the ERC worth some €1.5 million in funding. The Proof of Concept Grant will now build on this work already done. “Our aim is to validate the use of nanobodies to combat inflammaging and license this technology or its applications for industrial partners,” Franklin says. He believes that the project has the potential to alleviate the effects of inflammation and thus potentially save countless lives and the economic cost of illness.

Contact

Prof. Dr. Bernardo S. Franklin

Institute for Innate Immunity

University Hospital Bonn

Phone +49 228 28751981

Email: franklin@uni-bonn.de

Related news

Prof. Dr. Elvira Mass (left) and Prof. Dr. Tatjana Tchumatchenko (right)

News categories: Honors & Funding

Hunting for New Angles

New research questions often arise where different methods, mindsets and subject-specific cultures meet, and it is these kinds of encounter that Professor Elvira Mass and Professor Tatjana Tchumatchenko want to make happen in a targeted way in future. The two researchers have been picked as Henriette Herz Scouts by the Alexander von Humboldt Foundation.
View entry
Precise Konsortium

News categories: Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry
Prof. Dr. Jörg Wenzel

News categories: Honors & Funding

Jörg Wenzel elected chair of EADV Task Force on Cutaneous Lupus Erythematosus (CLE)

The European Academy of Dermatology and Venereology (EADV) has establishment a new Task Force on Cutaneous Lupus Erythematosus (CLE), led by ImmunoSensation³ member Jörg Wenzel. CLE, as autoimmune disease of the skin, is a prime example of chronic inflammatory dysregulation, leading to a severe disease burden. The treatment of cutaneous lupus continues to face unresolved clinical challenges. The CLE Task Force is set up to push the boundaries of clinical care, update guidelines, and advance collaborative research across Europe.
EADV Task Forces

Back to the news overview